New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates.
作者信息
Pasipanodya Jotam, Srivastava Shashikant, Gumbo Tawanda
出版信息
Antimicrob Agents Chemother. 2012 Oct;56(10):5428. doi: 10.1128/AAC.00976-12.
Abstract
摘要
相似文献
1
New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates.结核分枝杆菌分离株的新药敏折点及最低抑菌浓度分布的区域变异性
Antimicrob Agents Chemother. 2012 Oct;56(10):5428. doi: 10.1128/AAC.00976-12.
2
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.氧氟沙星在南非耐多药结核病患者中的群体药代动力学和药效学
Antimicrob Agents Chemother. 2012 Jul;56(7):3857-63. doi: 10.1128/AAC.00048-12. Epub 2012 May 7.
3
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.鞘内注射左氧氟沙星和阿米卡星治疗耐多药结核分枝杆菌引起的脑膜炎：病例报告
Clin Infect Dis. 2001 Feb 15;32(4):643-6. doi: 10.1086/318698. Epub 2001 Feb 9.
4
5
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.南非儿童中左氧氟沙星不敏感肺炎链球菌的出现及耐多药结核病的治疗：一项队列观察性监测研究
Lancet. 2008 Mar 29;371(9618):1108-13. doi: 10.1016/S0140-6736(08)60350-5. Epub 2008 Mar 21.
6
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.中国耐多药结核病治疗中与临床结局相关的二线药物最低抑菌浓度断点的确定
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4786-92. doi: 10.1128/AAC.03008-15. Print 2016 Aug.
7
Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India.印度结核分枝杆菌临床分离株中氟喹诺酮耐药性分析。
J Chemother. 2007 Apr;19(2):166-71. doi: 10.1179/joc.2007.19.2.166.
8
[Combination chemotherapy of drug-resistant tuberculosis with inclusion of ofloxacin (zanocin)].
Antibiot Khimioter. 2001;46(8):9-18.
9
Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis.氧氟沙星在耐药结核病中的肺内药代动力学
Int J Tuberc Lung Dis. 2001 Mar;5(3):278-82.
10
Tuberculosis drug resistance comes full circle.
Lancet. 2008 Mar 29;371(9618):1052-3. doi: 10.1016/S0140-6736(08)60464-X.
引用本文的文献
1
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.应用蒙特卡罗实验确定德拉马尼的药代动力学/药效学敏感性折点。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0140122. doi: 10.1128/aac.01401-22. Epub 2023 Mar 6.
2
Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.秘鲁分枝杆菌药敏试验肉汤微量稀释板法评估。
BMC Infect Dis. 2022 Aug 24;22(1):705. doi: 10.1186/s12879-022-07677-9.
3
Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India.野生型最低抑菌浓度分布用于重新评估印度南部结核病患者抗结核药物的临界浓度和药效学
Front Microbiol. 2020 Jun 30;11:1182. doi: 10.3389/fmicb.2020.01182. eCollection 2020.
4
Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population.北方邦东部人群中N-乙酰转移酶2基因多态性与抗结核药物性肝毒性的关联
Cureus. 2019 Apr 10;11(4):e4425. doi: 10.7759/cureus.4425.
5
The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.临床药代动力学-药效学研究在揭示结核病早期和晚期结局决定因素中的重要性。
Int J Pharmacokinet. 2017 Aug;2(3):195-212. doi: 10.4155/ipk-2017-0004. Epub 2017 Jul 12.
6
Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.印度耐多药结核病儿童二线抗结核药物的药代动力学。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02410-17. Print 2018 May.
7
A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.基于药效学靶点设定的儿童结核病联合治疗方案设计程序：操场设计规则
Clin Infect Dis. 2016 Nov 1;63(suppl 3):S75-S79. doi: 10.1093/cid/ciw472.
8
A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.一项多实验室、多国研究，以确定选定的一线抗结核药物、二线注射剂、氟喹诺酮类、氯法齐明和利奈唑胺的表型药敏试验的最低抑菌浓度（MIC）质量控制范围。
J Clin Microbiol. 2016 Dec;54(12):2963-2968. doi: 10.1128/JCM.01138-16. Epub 2016 Sep 21.
9
Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.人工智能与阿米卡星暴露对耐多药结核病患者预后的预测
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5928-32. doi: 10.1128/AAC.00962-16. Print 2016 Oct.
10
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.优化一线抗结核药物的治疗效果：治疗药物监测的作用
Eur J Clin Pharmacol. 2016 Aug;72(8):905-16. doi: 10.1007/s00228-016-2083-4. Epub 2016 Jun 15.
本文引用的文献
1
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.氧氟沙星在南非耐多药结核病患者中的群体药代动力学和药效学
Antimicrob Agents Chemother. 2012 Jul;56(7):3857-63. doi: 10.1128/AAC.00048-12. Epub 2012 May 7.
2
Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis.与表型隐匿性耐多药结核分枝杆菌 rpoB 突变相关的临床失败。
Int J Tuberc Lung Dis. 2012 Feb;16(2):216-20. doi: 10.5588/ijtld.11.0178.
3
Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.必须考虑野生型最低抑菌浓度（MIC）分布情况，以便为包括结核分枝杆菌在内的所有细菌病原体设定具有临床意义的药敏试验断点。
Antimicrob Agents Chemother. 2011 Sep;55(9):4492-3; author reply 4493. doi: 10.1128/AAC.00232-11.
4
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.基于抗菌药物药代动力学/药效学科学和群体药代动力学变异性的一线抗结核药物新药敏断点。
Antimicrob Agents Chemother. 2010 Apr;54(4):1484-91. doi: 10.1128/AAC.01474-09. Epub 2010 Jan 19.
5
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.利用临床前数据选择埃维霉素的II/III期剂量并确定临床前最低抑菌浓度（MIC）断点。
Antimicrob Agents Chemother. 2001 Jan;45(1):13-22. doi: 10.1128/AAC.45.1.13-22.2001.
Zotero 插件